Membranoproliferative Glomerulonephritis: A Prospective Clinical Trial of Platelet-Inhibitor Therapy
Forty patients with Type I membranoproliferative glomerulonephritis were treated for one year with dipyridamole, 225 mg per day, and aspirin, 975 mg per day, in a prospective, randomized, double-blind, placebo-controlled study. At the base line, the half-life of 51 Cr-labeled platelets was reduced i...
Gespeichert in:
| Veröffentlicht in: | N.Engl. J. Med.; (United States) 1984-05, Vol.310 (22), p.1421-1426 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1426 |
|---|---|
| container_issue | 22 |
| container_start_page | 1421 |
| container_title | N.Engl. J. Med.; (United States) |
| container_volume | 310 |
| creator | Donadio, James V Anderson, Carl F Mitchell, John C Holley, Keith E Ilstrup, Duane M Fuster, Valentin Chesebro, James H |
| description | Forty patients with Type I membranoproliferative glomerulonephritis were treated for one year with dipyridamole, 225 mg per day, and aspirin, 975 mg per day, in a prospective, randomized, double-blind, placebo-controlled study. At the base line, the half-life of
51
Cr-labeled platelets was reduced in 12 of 17 patients. The platelet half-life became longer and renal function stabilized in the treated group, as compared with the placebo group, suggesting a relation between platelet consumption and the glomerulopathy. The glomerular filtration rate, determined by iothalamate clearance, was better maintained in the treated group (average decrease, 1.3 ml per minute per 1.73 m
2
of body-surface area per 12 months) than in the placebo group (average decrease, 19.6). Fewer patients in the treated group than in the placebo group had progression to end-stage renal disease (3 of 21 after 62 months as compared with 9 of 19 after 33 months). The data suggest that dipyridamole and aspirin slowed the deterioration of renal function and the development of end-stage renal disease. (N Engl J Med 1984; 310:1421–6.)
MEMBRANOPROLIFERATIVE glomerulonephritis is a primary glomerular disease with distinct morphologic patterns. It affects children and adults, is poorly understood, and is associated with a high but variable rate of progression to renal failure.
1
2
3
4
5
6
Contrary to uncontrolled studies,
7
8
9
three randomized controlled trials showed no beneficial effects on renal function and glomerular morphologic features after treatment with prednisone
10
or a combination of cyclophosphamide, dipyridamole, and warfarin sodium.
11
,
12
The rationale for the use of platelet-inhibitor drugs in glomerulonephritis stems from the demonstrations of platelet activation in glomerulonephritis,
13
14
15
arterial smooth-muscle-cell proliferation by platelet factors,
16
and increased platelet consumption in various vascular
17
18
19
and renal
20
21
diseases, . . . |
| doi_str_mv | 10.1056/NEJM198405313102203 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_proquest_miscellaneous_81044909</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>81044909</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-6185ef9ea86d21bd08f316f957e72b373bc8d82b07ed42f54f8f4db629167222</originalsourceid><addsrcrecordid>eNp90ElLJTEQB_AgI85z-QQyIOMwCNJaWTrLUcQVl4v30J2uYB7dnTdJt-C3N8N7eJBhcqlD_apS_Ak5pHBGoZbnT1f3j9RoATWnnAJjwLfIgtacV0KA_EYWAExXQhn-nezmvITyqDA7ZEdyVVy9ICePOLSpGeMqxT54TM0U3vDopo8DprmPI65eU5hC3ifbvukzHmzqHnm5vnq5vK0enm_uLi8eKifATJWkukZvsNGyY7TtQHtOpTe1QsVarnjrdKdZCwo7wXwtvPaiayUzVCrG2B75uV4b8xRsdmFC9-riOKKbrFRCaw4F_V6jcvSfGfNkh5Ad9n0zYpyz1RSEMGAKPP4Cl3FOY7nfUq0kGKgZLYqvlUsx54TerlIYmvRuKdi_Sdt_JF2mfmx2z-2A3efMJtrS_7XpN9k1vS8hu5A_mZGKC64LO12zYch2xOXw308_AJsej1I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1876090521</pqid></control><display><type>article</type><title>Membranoproliferative Glomerulonephritis: A Prospective Clinical Trial of Platelet-Inhibitor Therapy</title><source>MEDLINE</source><creator>Donadio, James V ; Anderson, Carl F ; Mitchell, John C ; Holley, Keith E ; Ilstrup, Duane M ; Fuster, Valentin ; Chesebro, James H</creator><creatorcontrib>Donadio, James V ; Anderson, Carl F ; Mitchell, John C ; Holley, Keith E ; Ilstrup, Duane M ; Fuster, Valentin ; Chesebro, James H ; Department of Medical Statistics and Epidemiology, Mayo Clinic, Rochester, MN</creatorcontrib><description>Forty patients with Type I membranoproliferative glomerulonephritis were treated for one year with dipyridamole, 225 mg per day, and aspirin, 975 mg per day, in a prospective, randomized, double-blind, placebo-controlled study. At the base line, the half-life of
51
Cr-labeled platelets was reduced in 12 of 17 patients. The platelet half-life became longer and renal function stabilized in the treated group, as compared with the placebo group, suggesting a relation between platelet consumption and the glomerulopathy. The glomerular filtration rate, determined by iothalamate clearance, was better maintained in the treated group (average decrease, 1.3 ml per minute per 1.73 m
2
of body-surface area per 12 months) than in the placebo group (average decrease, 19.6). Fewer patients in the treated group than in the placebo group had progression to end-stage renal disease (3 of 21 after 62 months as compared with 9 of 19 after 33 months). The data suggest that dipyridamole and aspirin slowed the deterioration of renal function and the development of end-stage renal disease. (N Engl J Med 1984; 310:1421–6.)
MEMBRANOPROLIFERATIVE glomerulonephritis is a primary glomerular disease with distinct morphologic patterns. It affects children and adults, is poorly understood, and is associated with a high but variable rate of progression to renal failure.
1
2
3
4
5
6
Contrary to uncontrolled studies,
7
8
9
three randomized controlled trials showed no beneficial effects on renal function and glomerular morphologic features after treatment with prednisone
10
or a combination of cyclophosphamide, dipyridamole, and warfarin sodium.
11
,
12
The rationale for the use of platelet-inhibitor drugs in glomerulonephritis stems from the demonstrations of platelet activation in glomerulonephritis,
13
14
15
arterial smooth-muscle-cell proliferation by platelet factors,
16
and increased platelet consumption in various vascular
17
18
19
and renal
20
21
diseases, . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM198405313102203</identifier><identifier>PMID: 6371535</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>ACETYLSALICYLIC ACID ; Adolescent ; Adult ; Aged ; ANALGESICS ; ANTIPYRETICS ; Aspirin ; Aspirin - administration & dosage ; Aspirin - pharmacology ; Aspirin - therapeutic use ; BASIC BIOLOGICAL SCIENCES ; BETA DECAY RADIOISOTOPES ; Biological and medical sciences ; BIOLOGICAL MATERIALS ; Biopsy ; BLOOD ; BLOOD CELLS ; BLOOD PLATELETS ; Blood Platelets - drug effects ; BODY FLUIDS ; CARBOXYLIC ACIDS ; Cell Survival - drug effects ; CENTRAL NERVOUS SYSTEM DEPRESSANTS ; CHEMOTHERAPY ; Child ; CHROMIUM 51 ; CHROMIUM ISOTOPES ; Chromium Radioisotopes ; Clinical Trials as Topic ; Dipyridamole ; Dipyridamole - administration & dosage ; Dipyridamole - pharmacology ; Dipyridamole - therapeutic use ; Disease ; DISEASES ; Double-Blind Method ; Drug Therapy, Combination ; DRUGS ; ELECTRON CAPTURE RADIOISOTOPES ; End-stage renal disease ; EVEN-ODD NUCLEI ; Failure ; Female ; Glomerular filtration rate ; Glomerulonephritis ; Glomerulonephritis - drug therapy ; Half-Life ; Humans ; HYDROXY ACIDS ; INTERMEDIATE MASS NUCLEI ; Internal medicine ; Iothalamic Acid ; ISOTOPE APPLICATIONS ; ISOTOPES ; Kidney diseases ; Kidney transplantation ; LABELLING ; Laboratories ; Male ; MATERIALS ; Medical sciences ; Microscopy ; Middle Aged ; NUCLEI ; ORGANIC ACIDS ; ORGANIC COMPOUNDS ; PATIENTS ; Pharmacology. Drug treatments ; Platelets ; Prospective Studies ; RADIOISOTOPES ; Random Allocation ; Renal function ; THERAPY 550901 -- Pathology-- Tracer Techniques ; TRACER TECHNIQUES ; Urinary system ; Urine ; UROGENITAL SYSTEM DISEASES</subject><ispartof>N.Engl. J. Med.; (United States), 1984-05, Vol.310 (22), p.1421-1426</ispartof><rights>1984 INIST-CNRS</rights><rights>Copyright Massachusetts Medical Society May 31, 1984</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c409t-6185ef9ea86d21bd08f316f957e72b373bc8d82b07ed42f54f8f4db629167222</cites></display><links><openurl>$$Topenurl_article</openurl><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>776,881</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=9673438$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6371535$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/6748830$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Donadio, James V</creatorcontrib><creatorcontrib>Anderson, Carl F</creatorcontrib><creatorcontrib>Mitchell, John C</creatorcontrib><creatorcontrib>Holley, Keith E</creatorcontrib><creatorcontrib>Ilstrup, Duane M</creatorcontrib><creatorcontrib>Fuster, Valentin</creatorcontrib><creatorcontrib>Chesebro, James H</creatorcontrib><creatorcontrib>Department of Medical Statistics and Epidemiology, Mayo Clinic, Rochester, MN</creatorcontrib><title>Membranoproliferative Glomerulonephritis: A Prospective Clinical Trial of Platelet-Inhibitor Therapy</title><title>N.Engl. J. Med.; (United States)</title><addtitle>N Engl J Med</addtitle><description>Forty patients with Type I membranoproliferative glomerulonephritis were treated for one year with dipyridamole, 225 mg per day, and aspirin, 975 mg per day, in a prospective, randomized, double-blind, placebo-controlled study. At the base line, the half-life of
51
Cr-labeled platelets was reduced in 12 of 17 patients. The platelet half-life became longer and renal function stabilized in the treated group, as compared with the placebo group, suggesting a relation between platelet consumption and the glomerulopathy. The glomerular filtration rate, determined by iothalamate clearance, was better maintained in the treated group (average decrease, 1.3 ml per minute per 1.73 m
2
of body-surface area per 12 months) than in the placebo group (average decrease, 19.6). Fewer patients in the treated group than in the placebo group had progression to end-stage renal disease (3 of 21 after 62 months as compared with 9 of 19 after 33 months). The data suggest that dipyridamole and aspirin slowed the deterioration of renal function and the development of end-stage renal disease. (N Engl J Med 1984; 310:1421–6.)
MEMBRANOPROLIFERATIVE glomerulonephritis is a primary glomerular disease with distinct morphologic patterns. It affects children and adults, is poorly understood, and is associated with a high but variable rate of progression to renal failure.
1
2
3
4
5
6
Contrary to uncontrolled studies,
7
8
9
three randomized controlled trials showed no beneficial effects on renal function and glomerular morphologic features after treatment with prednisone
10
or a combination of cyclophosphamide, dipyridamole, and warfarin sodium.
11
,
12
The rationale for the use of platelet-inhibitor drugs in glomerulonephritis stems from the demonstrations of platelet activation in glomerulonephritis,
13
14
15
arterial smooth-muscle-cell proliferation by platelet factors,
16
and increased platelet consumption in various vascular
17
18
19
and renal
20
21
diseases, . . .</description><subject>ACETYLSALICYLIC ACID</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>ANALGESICS</subject><subject>ANTIPYRETICS</subject><subject>Aspirin</subject><subject>Aspirin - administration & dosage</subject><subject>Aspirin - pharmacology</subject><subject>Aspirin - therapeutic use</subject><subject>BASIC BIOLOGICAL SCIENCES</subject><subject>BETA DECAY RADIOISOTOPES</subject><subject>Biological and medical sciences</subject><subject>BIOLOGICAL MATERIALS</subject><subject>Biopsy</subject><subject>BLOOD</subject><subject>BLOOD CELLS</subject><subject>BLOOD PLATELETS</subject><subject>Blood Platelets - drug effects</subject><subject>BODY FLUIDS</subject><subject>CARBOXYLIC ACIDS</subject><subject>Cell Survival - drug effects</subject><subject>CENTRAL NERVOUS SYSTEM DEPRESSANTS</subject><subject>CHEMOTHERAPY</subject><subject>Child</subject><subject>CHROMIUM 51</subject><subject>CHROMIUM ISOTOPES</subject><subject>Chromium Radioisotopes</subject><subject>Clinical Trials as Topic</subject><subject>Dipyridamole</subject><subject>Dipyridamole - administration & dosage</subject><subject>Dipyridamole - pharmacology</subject><subject>Dipyridamole - therapeutic use</subject><subject>Disease</subject><subject>DISEASES</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>DRUGS</subject><subject>ELECTRON CAPTURE RADIOISOTOPES</subject><subject>End-stage renal disease</subject><subject>EVEN-ODD NUCLEI</subject><subject>Failure</subject><subject>Female</subject><subject>Glomerular filtration rate</subject><subject>Glomerulonephritis</subject><subject>Glomerulonephritis - drug therapy</subject><subject>Half-Life</subject><subject>Humans</subject><subject>HYDROXY ACIDS</subject><subject>INTERMEDIATE MASS NUCLEI</subject><subject>Internal medicine</subject><subject>Iothalamic Acid</subject><subject>ISOTOPE APPLICATIONS</subject><subject>ISOTOPES</subject><subject>Kidney diseases</subject><subject>Kidney transplantation</subject><subject>LABELLING</subject><subject>Laboratories</subject><subject>Male</subject><subject>MATERIALS</subject><subject>Medical sciences</subject><subject>Microscopy</subject><subject>Middle Aged</subject><subject>NUCLEI</subject><subject>ORGANIC ACIDS</subject><subject>ORGANIC COMPOUNDS</subject><subject>PATIENTS</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelets</subject><subject>Prospective Studies</subject><subject>RADIOISOTOPES</subject><subject>Random Allocation</subject><subject>Renal function</subject><subject>THERAPY 550901 -- Pathology-- Tracer Techniques</subject><subject>TRACER TECHNIQUES</subject><subject>Urinary system</subject><subject>Urine</subject><subject>UROGENITAL SYSTEM DISEASES</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>false</fulltext><rsrctype>article</rsrctype><creationdate>1984</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp90ElLJTEQB_AgI85z-QQyIOMwCNJaWTrLUcQVl4v30J2uYB7dnTdJt-C3N8N7eJBhcqlD_apS_Ak5pHBGoZbnT1f3j9RoATWnnAJjwLfIgtacV0KA_EYWAExXQhn-nezmvITyqDA7ZEdyVVy9ICePOLSpGeMqxT54TM0U3vDopo8DprmPI65eU5hC3ifbvukzHmzqHnm5vnq5vK0enm_uLi8eKifATJWkukZvsNGyY7TtQHtOpTe1QsVarnjrdKdZCwo7wXwtvPaiayUzVCrG2B75uV4b8xRsdmFC9-riOKKbrFRCaw4F_V6jcvSfGfNkh5Ad9n0zYpyz1RSEMGAKPP4Cl3FOY7nfUq0kGKgZLYqvlUsx54TerlIYmvRuKdi_Sdt_JF2mfmx2z-2A3efMJtrS_7XpN9k1vS8hu5A_mZGKC64LO12zYch2xOXw308_AJsej1I</recordid><startdate>19840531</startdate><enddate>19840531</enddate><creator>Donadio, James V</creator><creator>Anderson, Carl F</creator><creator>Mitchell, John C</creator><creator>Holley, Keith E</creator><creator>Ilstrup, Duane M</creator><creator>Fuster, Valentin</creator><creator>Chesebro, James H</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>OTOTI</scope></search><sort><creationdate>19840531</creationdate><title>Membranoproliferative Glomerulonephritis</title><author>Donadio, James V ; Anderson, Carl F ; Mitchell, John C ; Holley, Keith E ; Ilstrup, Duane M ; Fuster, Valentin ; Chesebro, James H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-6185ef9ea86d21bd08f316f957e72b373bc8d82b07ed42f54f8f4db629167222</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1984</creationdate><topic>ACETYLSALICYLIC ACID</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>ANALGESICS</topic><topic>ANTIPYRETICS</topic><topic>Aspirin</topic><topic>Aspirin - administration & dosage</topic><topic>Aspirin - pharmacology</topic><topic>Aspirin - therapeutic use</topic><topic>BASIC BIOLOGICAL SCIENCES</topic><topic>BETA DECAY RADIOISOTOPES</topic><topic>Biological and medical sciences</topic><topic>BIOLOGICAL MATERIALS</topic><topic>Biopsy</topic><topic>BLOOD</topic><topic>BLOOD CELLS</topic><topic>BLOOD PLATELETS</topic><topic>Blood Platelets - drug effects</topic><topic>BODY FLUIDS</topic><topic>CARBOXYLIC ACIDS</topic><topic>Cell Survival - drug effects</topic><topic>CENTRAL NERVOUS SYSTEM DEPRESSANTS</topic><topic>CHEMOTHERAPY</topic><topic>Child</topic><topic>CHROMIUM 51</topic><topic>CHROMIUM ISOTOPES</topic><topic>Chromium Radioisotopes</topic><topic>Clinical Trials as Topic</topic><topic>Dipyridamole</topic><topic>Dipyridamole - administration & dosage</topic><topic>Dipyridamole - pharmacology</topic><topic>Dipyridamole - therapeutic use</topic><topic>Disease</topic><topic>DISEASES</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>DRUGS</topic><topic>ELECTRON CAPTURE RADIOISOTOPES</topic><topic>End-stage renal disease</topic><topic>EVEN-ODD NUCLEI</topic><topic>Failure</topic><topic>Female</topic><topic>Glomerular filtration rate</topic><topic>Glomerulonephritis</topic><topic>Glomerulonephritis - drug therapy</topic><topic>Half-Life</topic><topic>Humans</topic><topic>HYDROXY ACIDS</topic><topic>INTERMEDIATE MASS NUCLEI</topic><topic>Internal medicine</topic><topic>Iothalamic Acid</topic><topic>ISOTOPE APPLICATIONS</topic><topic>ISOTOPES</topic><topic>Kidney diseases</topic><topic>Kidney transplantation</topic><topic>LABELLING</topic><topic>Laboratories</topic><topic>Male</topic><topic>MATERIALS</topic><topic>Medical sciences</topic><topic>Microscopy</topic><topic>Middle Aged</topic><topic>NUCLEI</topic><topic>ORGANIC ACIDS</topic><topic>ORGANIC COMPOUNDS</topic><topic>PATIENTS</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelets</topic><topic>Prospective Studies</topic><topic>RADIOISOTOPES</topic><topic>Random Allocation</topic><topic>Renal function</topic><topic>THERAPY 550901 -- Pathology-- Tracer Techniques</topic><topic>TRACER TECHNIQUES</topic><topic>Urinary system</topic><topic>Urine</topic><topic>UROGENITAL SYSTEM DISEASES</topic><toplevel>peer_reviewed</toplevel><creatorcontrib>Donadio, James V</creatorcontrib><creatorcontrib>Anderson, Carl F</creatorcontrib><creatorcontrib>Mitchell, John C</creatorcontrib><creatorcontrib>Holley, Keith E</creatorcontrib><creatorcontrib>Ilstrup, Duane M</creatorcontrib><creatorcontrib>Fuster, Valentin</creatorcontrib><creatorcontrib>Chesebro, James H</creatorcontrib><creatorcontrib>Department of Medical Statistics and Epidemiology, Mayo Clinic, Rochester, MN</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>Biological Sciences</collection><collection>ProQuest Consumer Health Database</collection><collection>ProQuest Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>ProQuest Research Library</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><jtitle>N.Engl. J. Med.; (United States)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>no_fulltext</fulltext></delivery><addata><au>Donadio, James V</au><au>Anderson, Carl F</au><au>Mitchell, John C</au><au>Holley, Keith E</au><au>Ilstrup, Duane M</au><au>Fuster, Valentin</au><au>Chesebro, James H</au><aucorp>Department of Medical Statistics and Epidemiology, Mayo Clinic, Rochester, MN</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Membranoproliferative Glomerulonephritis: A Prospective Clinical Trial of Platelet-Inhibitor Therapy</atitle><jtitle>N.Engl. J. Med.; (United States)</jtitle><addtitle>N Engl J Med</addtitle><date>1984-05-31</date><risdate>1984</risdate><volume>310</volume><issue>22</issue><spage>1421</spage><epage>1426</epage><pages>1421-1426</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Forty patients with Type I membranoproliferative glomerulonephritis were treated for one year with dipyridamole, 225 mg per day, and aspirin, 975 mg per day, in a prospective, randomized, double-blind, placebo-controlled study. At the base line, the half-life of
51
Cr-labeled platelets was reduced in 12 of 17 patients. The platelet half-life became longer and renal function stabilized in the treated group, as compared with the placebo group, suggesting a relation between platelet consumption and the glomerulopathy. The glomerular filtration rate, determined by iothalamate clearance, was better maintained in the treated group (average decrease, 1.3 ml per minute per 1.73 m
2
of body-surface area per 12 months) than in the placebo group (average decrease, 19.6). Fewer patients in the treated group than in the placebo group had progression to end-stage renal disease (3 of 21 after 62 months as compared with 9 of 19 after 33 months). The data suggest that dipyridamole and aspirin slowed the deterioration of renal function and the development of end-stage renal disease. (N Engl J Med 1984; 310:1421–6.)
MEMBRANOPROLIFERATIVE glomerulonephritis is a primary glomerular disease with distinct morphologic patterns. It affects children and adults, is poorly understood, and is associated with a high but variable rate of progression to renal failure.
1
2
3
4
5
6
Contrary to uncontrolled studies,
7
8
9
three randomized controlled trials showed no beneficial effects on renal function and glomerular morphologic features after treatment with prednisone
10
or a combination of cyclophosphamide, dipyridamole, and warfarin sodium.
11
,
12
The rationale for the use of platelet-inhibitor drugs in glomerulonephritis stems from the demonstrations of platelet activation in glomerulonephritis,
13
14
15
arterial smooth-muscle-cell proliferation by platelet factors,
16
and increased platelet consumption in various vascular
17
18
19
and renal
20
21
diseases, . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>6371535</pmid><doi>10.1056/NEJM198405313102203</doi><tpages>6</tpages></addata></record> |
| fulltext | no_fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | N.Engl. J. Med.; (United States), 1984-05, Vol.310 (22), p.1421-1426 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_81044909 |
| source | MEDLINE |
| subjects | ACETYLSALICYLIC ACID Adolescent Adult Aged ANALGESICS ANTIPYRETICS Aspirin Aspirin - administration & dosage Aspirin - pharmacology Aspirin - therapeutic use BASIC BIOLOGICAL SCIENCES BETA DECAY RADIOISOTOPES Biological and medical sciences BIOLOGICAL MATERIALS Biopsy BLOOD BLOOD CELLS BLOOD PLATELETS Blood Platelets - drug effects BODY FLUIDS CARBOXYLIC ACIDS Cell Survival - drug effects CENTRAL NERVOUS SYSTEM DEPRESSANTS CHEMOTHERAPY Child CHROMIUM 51 CHROMIUM ISOTOPES Chromium Radioisotopes Clinical Trials as Topic Dipyridamole Dipyridamole - administration & dosage Dipyridamole - pharmacology Dipyridamole - therapeutic use Disease DISEASES Double-Blind Method Drug Therapy, Combination DRUGS ELECTRON CAPTURE RADIOISOTOPES End-stage renal disease EVEN-ODD NUCLEI Failure Female Glomerular filtration rate Glomerulonephritis Glomerulonephritis - drug therapy Half-Life Humans HYDROXY ACIDS INTERMEDIATE MASS NUCLEI Internal medicine Iothalamic Acid ISOTOPE APPLICATIONS ISOTOPES Kidney diseases Kidney transplantation LABELLING Laboratories Male MATERIALS Medical sciences Microscopy Middle Aged NUCLEI ORGANIC ACIDS ORGANIC COMPOUNDS PATIENTS Pharmacology. Drug treatments Platelets Prospective Studies RADIOISOTOPES Random Allocation Renal function THERAPY 550901 -- Pathology-- Tracer Techniques TRACER TECHNIQUES Urinary system Urine UROGENITAL SYSTEM DISEASES |
| title | Membranoproliferative Glomerulonephritis: A Prospective Clinical Trial of Platelet-Inhibitor Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T18%3A46%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Membranoproliferative%20Glomerulonephritis:%20A%20Prospective%20Clinical%20Trial%20of%20Platelet-Inhibitor%20Therapy&rft.jtitle=N.Engl.%20J.%20Med.;%20(United%20States)&rft.au=Donadio,%20James%20V&rft.aucorp=Department%20of%20Medical%20Statistics%20and%20Epidemiology,%20Mayo%20Clinic,%20Rochester,%20MN&rft.date=1984-05-31&rft.volume=310&rft.issue=22&rft.spage=1421&rft.epage=1426&rft.pages=1421-1426&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM198405313102203&rft_dat=%3Cproquest_osti_%3E81044909%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1876090521&rft_id=info:pmid/6371535&rfr_iscdi=true |